Perhaps we are being a little unrealistic. When GNBT announced the China opportunity it was fairly straightforward. Then things started to get more complicated when they added conversations with other countries, and then with BARDA...especially BARDA, with the opportunity to get grant money. But with that grant money came a huge additional level of complication, preparation, back planning, partners etc etc, while they continued to develop their vaccine precursors. That’s a pretty heavy lift for a little company. I’m just speaking for me but I think it’s pretty astonishing that they are as far down the path as they are. I don’t believe for a second that any of the other companies/organizations that are in the vaccine race will have anything of substance before the Fall of this year. Generex is still competitive. Given their unique development and production technology, they may in fact be way ahead. Perhaps we will get a solid update during the soon to be scheduled conference call.